Can a targeted drug beat radiation for early-stage lymphoma?
NCT ID NCT07736950
First seen Jul 30, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This phase 3 trial compares the experimental drug surovatamig with standard involved-site radiotherapy (with or without rituximab) in people with limited-stage follicular lymphoma. The goal is to see if surovatamig can produce deeper, longer-lasting responses and reduce the chance of the cancer returning. Participants receive either four cycles of surovatamig or radiotherapy for three weeks, with or without additional rituximab, and are followed for up to five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surovatamig
- What this could lead to
- If it works, surovatamig could offer a more effective, non-radiation treatment option for limited-stage follicular lymphoma, potentially reducing relapse risk.
- What could go wrong
- This is an early-phase comparison; surovatamig may not prove superior to standard care and could have unknown side effects. The trial is relatively small.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a second CAR T-Cell infusion beat lymphoma that returns?